Giredestrant in Combination with Everolimus Ok’d for Breast Cancer

Share

FDA has approved Genentech’s Wilserdly (giredestrant), an oral estrogen receptor antagonist, in combination with everolimus for treating adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test. The approval notes the drug is intended for those whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting. 

The agency has also authorized the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations

Approval was based on data from the evERA Breast Cancer (NCT05306340) trial in 373 adults with ER+, HER2- locally advanced or metastatic breast cancer including 207 patients whose tumors had ESR1 mutations. “Circulating tumor DNA (ctDNA) was assessed centrally to determine ESR1 mutational (ESR1m) status using the FoundationOne Liquid CDx (F1LCDx) assay, limited to specific ESR1 mutations in the ligand binding domain,” an agency release says.

“The primary efficacy outcome measure was progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,” the agency says. “Additional efficacy endpoints included overall survival (OS) and objective response rate (ORR). The trial demonstrated a statistically significant improvement in PFS for giredestrant and everolimus compared with PCET and everolimus in patients whose tumors had ESR1 mutations… Median PFS was 10 months (95% CI: 8.1, 12.9) in the giredestrant and everolimus arm and 5.5 months (95% CI: 3.8, 5.6) in the PCET and everolimus arm.”

The most common adverse reactions in those receiving giredestrant plus everolimus were stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea. The most common laboratory abnormalities were decreased hemoglobin, decreased lymphocytes, decreased WBC count, increased AST, increased ALT, decreased neutrophils, decreased platelets, decreased calcium, decreased potassium, increased creatinine, and decreased sodium.

The prescribing information includes warnings and precautions for bradycardia and embryo-fetal toxicity.

Read more